Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
In this article, we will take a look at the 10 best penny stocks to buy in September. If you want to skip our discussion on the current US economic situation, go directly to the 5 Best Penny Stocks to Buy in September. The US equity markets have been experiencing a sell-off in the past three […]
As a result, Summit's stock price has gained a noteworthy 30% over the prior two trading days. The biotech's stock has been shooting higher in response to a recent insider buy by CEO Robert Duggan. Summit's share price has been under heavy pressure this year for two key reasons.
Summit Therapeutics Inc. ( NASDAQ:SMMT ) shareholders (or potential shareholders) will be happy to see that the Co-CEO...
Shares of Summit Therapeutics (NASDAQ: SMMT) were soaring 14% higher at 11:14 a.m. ET on Friday and had vaulted as much as 30% higher earlier in the day. The big gain came after the company submitted a regulatory filing to the U.S. Securities and Exchange Commission (SEC) following market close on Thursday. This filing showed that Summit Therapeutics CEO Robert Duggan recently bought 94,849,203 shares for a little over $92 million.
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2022. Financial Highlights Aggregate cash, accounts receivable, and tax credits receivable on June 30, 2022 totaled $74.0 million as compared to $89.0 million on December 31, 2021. Our cash balance on June 30, 2022 was $57.3 million as compared t
Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully-subscribed $100 million rights offering. The rights offering resulted in the sale of approximately 103 million shares of the Company’s common stock, par value $0.01 at a price of $0.97 per share. The Company received aggregate gross proceeds from the rights offering of $100 million; expenses associated with the of
Summit Provides Preliminary Update on Financial PositionMenlo Park, California, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on August 8, 2022 (the “Expiration Date”). Importantly, for stockholders whose shares of our common stock are held in a brokerage account or are otherwise not registered directly with t